LaunXP

LaunXP Focuses on the Development of New Drugs and New Dosage Forms, Prioritizing the Search for Medications to Meet Market Needs and Address Hard-to-Treat Cancers. Currently, in Addition to Developing 505(b)(1) New Chemical Entity Drugs, the Company is Also Conducting Research on 505(b)(2) New Drugs (Drug Repurposing).The Company Repurposes FDA-Approved Drugs and Investigates Their Anti-Cancer Mechanisms, Allowing the Developed Drugs to Not Only Possess the Market Advantage of First-in-Class Mechanisms but Also Shorten Development Time and Reduce Costs.To Enhance the Value and Market Competitiveness of Its Products, the Company Has Simultaneously Initiated Special Projects for the Development of Virus-Like Particle and Nano-Formulation Anti-Cancer New Drugs.